Time filter

Source Type

Purpose: To evaluate the efficacy and safety of lobaplatin combined with docetaxel as neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy (IMRT) for high-risk positive lymph node (N+) nasopharyngeal carcinoma (NPC). Methods: This study enrolled 37 primary high-risk N+ NPC patients. The neoadjuvant chemotherapy program consisted of lobaplatin (30 mg/m2, day 1) plus docetaxel (75 mg/m2, day 1) for two cycles, 3 weeks apart. Concurrently with IMJRT, patients received a chemotherapy program of lobaplatin 50mg/m2. Cycle repetition was every 21 days. The IMRT doses were planning target volume (PTV) 68-72 Gy for gross disease in the nasopharynx, and 66-70 Gy for positive lymph nodes in 33 FRACTIONS. The doses for high risk and low risk region PTV were 59.4 Gy in 33 fractions and 50.4 Gy in 28 fractions. Results: The median follow-up duration was 31 months (range 4-52). The 3-year overall survival (OS) was 74.3%. The 3-year distant metastasis-free survival (DMFS) was 67.4%. The 3-year locoregional relapse-free survival (LRFS) was 91.5%, and the 3-year progression-free survival (PFS) was 61.2%. The efficiency of short-term effects of neoadjuvant chemotherapy and chemoradiotherapy were 83.8% and 100.0%, respectively. Serious acute toxicities observed were neutropenia (97.3%), thrombocytopenia (83.8%) and anemia (81.1%). Conclusions: In patients with high-risk N+ NPC, lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with IMRT yielded excellent short-term results with mild and tolerable toxicities. Source

Cao D.Y.,Peking Union Medical College | Yang J.X.,Peking Union Medical College | Wu X.H.,Fudan University | Chen Y.L.,Cancer hospital of Hunan | And 10 more authors.
British Journal of Cancer | Year: 2013

Background: There are limited data comparing the prognosis and fertility outcomes of the patients with early cervical cancer treated by trans-vaginal radical trachelectomy (VRT) or abdominal radical trachelectomy (ART). The objective of this study was to compare the surgical and pathologic characteristics, the prognosis and fertility outcomes of the patients treated by VRT or ART. Methods: Matched-case study based on a prospectively maintained database of patients underwent radical trachelectomy in 10 centres of China was designed to compare the prognosis and fertility outcomes of the patients treated by VRT or ART. Results: Totally 150 cases, 77 in the VRT and 73 in the ART group, were included. VRT and ART provide similar surgical and pathological outcomes except larger specimens obtained by ART. In the ART group, no patient developed recurrent diseases, but, in the VRT group, 7 (9.8%) patients developed recurrent diseases and 2 (1.6%) patients died of the tumours (P = 0.035). The rate of pregnancy in the VRT group was significantly higher than those of ART (39.5% vs 8.8%; P = 0.003). The patients with tumour size >2 cm showed significant higher recurrent rate (11.6% vs 2.4%, P < 0.05) and lower pregnant rate (12.5% vs 32.1%, P = 0.094) compared with the patients with tumour size <2 cm. Conclusion: Patients treated by ART obtained better oncology results, but their fertility outcomes were unfavourable compared with VRT. Tumour size < 2 cm should be emphasised as an indication for radical trachelectomy for improving the outcome of fertility and prognosis. Copyright © 2013 Cancer Research UK. Source

Lin N.,Sun Yat Sen University | Chen Z.,Peoples Hospital of Hainan Province | Lu Y.,Sun Yat Sen University | Li Y.,Sun Yat Sen University | And 2 more authors.
Hepatology Research | Year: 2015

Aim: Cancer is not only influenced by specific tumor cells but also by the stromal microenvironment. Upon liver damage, activated hepatic stellate cells (aHSC) become highly proliferative myofibroblast-like cells and are thought to secrete molecules that influence development of hepatocellular carcinoma (HCC). The aim of this study was to investigate the role of aHSC in the development of HCC. Methods: To assess if aHSC secreted factor(s) that promote microvascular endothelial cell (MEC) tube formation, MEC were plated with aHSC-conditioned medium and tube formation analyzed by light microscopy. An established transendothelial migration assay with MEC was used to evaluate the role of aHSC in migration and metastasis. A novel in vitro and in vivo orthotopic mouse HCC tumor model was used to investigate angiogenic, proliferative and metastatic activity of aHSC. Results: We found that aHSC promoted angiogenesis both in vitro and in vivo through vascular endothelial growth factor (VEGF). aHSC-conditioned medium increased the ability of MEC to form tubes which was dependent upon aHSC-secreted VEGF. In addition, HCC orthogenic tumors derived from co-injection of H22 cells plus aHSC into the hepatic lobes of mice had greater cell proliferation and vascularization, as evaluated by the presence of CD34 and VEGF expression, than tumors resulting from H22 injections alone. aHSC also migrated from the primary tumor to sites of metastasis. Conclusion: Our findings support aHSC playing multiple roles in HCC development and metastasis. © 2014 The Japan Society of Hepatology. Source

Lin P.,Peoples Hospital of Hainan Province | Fu Q.,Peoples Hospital of Hainan Province
Journal of Sichuan University (Medical Science Edition) | Year: 2014

Objective To examine the association of collagen type I al (COLIAl) Spl polymorphism with intervertebral disc degeneration in Han elderly people. Methods The objects in this case-control study were the Han elderly people over 65-years-old. There were totally 375 intervertebral disc degeneration patients and 118 healthy controls matched in demographic characteristics recruited. The guanine (G) to thymidine (T) polymorphism in the first intron of COLIAl gene was detected by PCR. Detected the difference of genotype frequency distribution and allele frequency between case group and the control group. Results Hardy-Weinberg equilibrium was analyzed in both case and control group. Spl site was genotyped,and the polymorphisms distributed in line with Hardy-Weinberg equilibrium either in case or control groups. There was significant difference in genotype frequency of Spl between control group and case group. GG: 264 ( 70. 4%)/82 ( 69. 5%), GT: 102 (27. 2% )/26 ( 22. 0%) and TT: 9 ( 2. 4% )/10 ( 8. 5%), respectively; ( x 2= 9. 527, P = 0. 009 ). No significant difference in allele frequencies of SNP was found between case group and control group. G: 630 ( 84. 0%)/190 (80.5%) and T: 120 ( 16. 0%)/46 ( 19. 5%), respectively. (x 2 = 1. 563, P = 0. 211 ). Conclusion COLIAl Spl polymorphism may be a genetic risk factor related to intervertebral disc degeneration in Han elderly people. Source

Xu Q.,Southern Medical University | Pan J.,Peking University | Yu J.,Peoples Hospital of Hainan Province | Liu X.,Southern Medical University | And 6 more authors.
Diabetes Research and Clinical Practice | Year: 2013

Aims: To compare the efficacy and safety of daily lipoic acid (300-600. mg i.v.) plus methylcobalamin (500-1000. mg i.v. or im.) (LA-MC) with that of methylcobalamin alone (MC) on diabetic peripheral neuropathy (DPN). Methods: Electronic database were searched for studies published up to November 1, 2012 and study quality was assessed in duplicate. A random or a fixed effect model was used to analyse outcomes which were expressed as risk ratios (RRs) or mean difference (MD). I2 statistic was used to assess heterogeneity. Results: Seventeen studies were included. Combined data from all studies showed that the LA-MC combination therapy was significantly superior to MC monotherapy (RR = 1.47; 95% CI: 1.37-1.58). Superiority of the LA-MC combination was shown in nerve conduction velocity (NCV) with WMDs of 6.89 (95% CI: 4.24-9.73) for median motor nerve conduction velocity (MNCV), 5.24 (4.14-6.34) for median sensory nerve conduction velocity (SNCV), 4.34 (3.03-5.64) for peroneal MNCV, and 4.53 (3.2-5.85) for peroneal SNCV. There were no serious adverse events associated with treatment. Conclusions: The results of the meta-analysis show that treatment with LA-MC for 2-4. weeks is associated with better outcomes in NCV and neuropathic symptoms relative to MC treatment. However larger well-designed studies are required to confirm this conclusion. © 2013 Elsevier Ireland Ltd. Source

Discover hidden collaborations